NASDAQ:SAVA Cassava Sciences (SAVA) Stock Price, News & Analysis $26.91 -2.54 (-8.62%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$26.50▼$29.8050-Day Range$9.57▼$35.0852-Week Range$8.79▼$42.20Volume1.54 million shsAverage Volume1.70 million shsMarket Capitalization$1.29 billionP/E RatioN/ADividend YieldN/APrice Target$119.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Cassava Sciences alerts: Email Address Cassava Sciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside342.2% Upside$119.00 Price TargetShort InterestHealthy36.85% of Shares Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment0.24Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.15 out of 5 starsMedical Sector314th out of 910 stocksPharmaceutical Preparations Industry132nd out of 426 stocks 3.3 Analyst's Opinion Consensus RatingCassava Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCassava Sciences has only been the subject of 2 research reports in the past 90 days.Read more about Cassava Sciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted36.85% of the outstanding shares of Cassava Sciences have been sold short.Short Interest Ratio / Days to CoverCassava Sciences has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Cassava Sciences has recently decreased by 7.09%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCassava Sciences does not currently pay a dividend.Dividend GrowthCassava Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCassava Sciences has received a 74.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for Alzheimer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Cassava Sciences is -0.82. Previous Next 1.2 News and Social Media Coverage News SentimentCassava Sciences has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Cassava Sciences this week, compared to 5 articles on an average week.Search InterestOnly 42 people have searched for SAVA on MarketBeat in the last 30 days. This is a decrease of -28% compared to the previous 30 days.MarketBeat FollowsOnly 18 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cassava Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.00% of the stock of Cassava Sciences is held by insiders.Percentage Held by InstitutionsOnly 38.05% of the stock of Cassava Sciences is held by institutions.Read more about Cassava Sciences' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Cassava Sciences is -12.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cassava Sciences is -12.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCassava Sciences has a P/B Ratio of 8.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cassava Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Cassava Sciences Stock (NASDAQ:SAVA)Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Read More SAVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SAVA Stock News HeadlinesAugust 10, 2024 | marketbeat.comCassava Sciences: A Hot Stock to Trade, Invest, or Avoid?Cassava Sciences has become a hot topic among traders due to its recent surge in volatility, liquidity, and overall market performance.September 5 at 8:46 AM | ca.finance.yahoo.comSAVA Nov 2024 22.500 callSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …September 3, 2024 | globenewswire.comCassava Sciences to Present at the H.C. Wainwright Global Investment ConferenceAugust 26, 2024 | finance.yahoo.comGlobal Wireless Brain Sensors Market to Accelerate Substantially at a CAGR of ~9% by 2030 | DelveInsightAugust 22, 2024 | uk.finance.yahoo.comCassava Sciences Inc (PX91.MU)August 19, 2024 | seekingalpha.comCassava Sciences: Volatility Provides Trading OpportunitiesAugust 18, 2024 | msn.comSilicon Motion Technology Corporation (SAVA): Evaluating Its Position Among Top Debt-Free StocksSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …August 13, 2024 | markets.businessinsider.comCautious Optimism Amidst Legal Challenges: Hold Rating on Cassava SciencesAugust 9, 2024 | markets.businessinsider.comJonesTrading Keeps Their Hold Rating on Cassava Sciences (SAVA)August 9, 2024 | benzinga.comBehind the Scenes of Cassava Sciences's Latest Options TrendsAugust 9, 2024 | msn.comCassava Sciences, Inc. (NASDAQ:SAVA) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comCassava Sciences down 15% following $40M loss contingency to resolve SEC probeAugust 8, 2024 | seekingalpha.comCassava Sciences: New CEO, Same Old ProblemsAugust 8, 2024 | seekingalpha.comCassava Sciences Q2 Earnings Review: So Many Questions, So Few AnswersAugust 8, 2024 | markets.businessinsider.comCassava Sciences Reports Q2 2024 Financial Results and Operational UpdatesAugust 8, 2024 | msn.comCassava Sciences estimates $40M loss contingency to resolve SEC simufilam probeSee More Headlines Receive SAVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SAVA CUSIPN/A CIK1069530 Webwww.cassavasciences.com Phone(512) 501-2444Fax512-501-0414Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$119.00 High Stock Price Target$131.00 Low Stock Price Target$107.00 Potential Upside/Downside+342.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-88.23% Return on Assets-68.31% Debt Debt-to-Equity RatioN/A Current Ratio4.07 Quick Ratio4.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.26 per share Price / Book8.25Miscellaneous Outstanding Shares47,976,000Free Float43,658,000Market Cap$1.29 billion OptionableOptionable Beta-0.63 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Remi Barbier (Age 64)Founder, Chairman, President & CEO Comp: $1.2MMr. Eric J. Schoen (Age 56)Chief Financial Officer Comp: $460kMr. R. Christopher Cook (Age 60)Senior VP, Company Secretary & General Counsel Comp: $425kDr. James W. Kupiec M.D. (Age 71)Chief Medical Officer Comp: $435kDr. George Thornton Ph.D.Senior Vice President of TechnologyMr. Michael ZamlootSenior Vice President of Technical OperationsDr. Michael Marsman Pharm.D.Senior Vice President of Regulatory AffairsDr. Lindsay H. Burns Ph.D.Senior Vice President of NeuroscienceMore ExecutivesKey CompetitorsCollegium PharmaceuticalNASDAQ:COLLNature's Sunshine ProductsNASDAQ:NATRVerastemNASDAQ:VSTMVerrica PharmaceuticalsNASDAQ:VRCAChimerixNASDAQ:CMRXView All CompetitorsInstitutional OwnershipAristides Capital LLCBought 16,235 shares on 8/23/2024Ownership: 0.034%Susquehanna International Group LLPBought 288,700 shares on 8/16/2024Ownership: 0.000%Perceptive Advisors LLCBought 183,000 shares on 8/16/2024Ownership: 0.000%The Manufacturers Life Insurance Company Bought 2,377 shares on 8/15/2024Ownership: 0.047%Dark Forest Capital Management LPBought 10,635 shares on 8/15/2024Ownership: 0.022%View All Institutional Transactions SAVA Stock Analysis - Frequently Asked Questions How have SAVA shares performed this year? Cassava Sciences' stock was trading at $22.51 at the start of the year. Since then, SAVA stock has increased by 19.5% and is now trading at $26.91. View the best growth stocks for 2024 here. How were Cassava Sciences' earnings last quarter? Cassava Sciences, Inc. (NASDAQ:SAVA) announced its quarterly earnings results on Thursday, August, 8th. The company reported $0.13 EPS for the quarter, topping analysts' consensus estimates of ($0.44) by $0.57. When did Cassava Sciences' stock split? Cassava Sciences shares split on the morning of Thursday, December 21st 2023. The 14-10 split was announced on Thursday, December 21st 2023. The newly minted shares were distributed to shareholders after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split. Who are Cassava Sciences' major shareholders? Cassava Sciences' top institutional investors include Susquehanna International Group LLP, Perceptive Advisors LLC, Clear Creek Financial Management LLC (0.30%) and Bank of New York Mellon Corp (0.29%). Insiders that own company stock include Eric Schoen and James William Kupiec. View institutional ownership trends. How do I buy shares of Cassava Sciences? Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cassava Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO) and DURECT (DRRX). This page (NASDAQ:SAVA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
